Loading patent…
AssigneeAptevo Research and Development LLC
InventorsLaura Sue Grosmaire, Martha Susan Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter Armstrong Thompson, Sandy Alexander Simon, William Brady
Estimating the term…
The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition; the invention provides humanized CD37-specific binding molecules.
-117. (canceled)
A humanized or chimeric CD37-specific binding molecule comprising a binding domain and immunoglobulin CH2 and CH3 domains, wherein the binding domain comprises:
A pharmaceutical composition comprising a humanized or chimeric CD37-specific binding molecule and one or more pharmaceutically acceptable carriers or additives, wherein the CD37-specific binding molecule comprises a binding domain and immunoglobulin CH2 and CH3 domains, wherein the binding domain comprises:
Dependencies are inferred from the claim text.